A radioreceptor assay for pharmaceutical preparations of insulin.
A radioreceptor assay has been developed that is suitable for the measurement of the potency of crystalline insulin and pharmaceutical insulin formulations. It utilizes the well characterized and widely available IM-9 human lymphocyte cell line as the source of receptor. Bovine, porcine and human crystalline and formulated insulins have been assayed against the 4th International and European Standards for Insulin and the potencies compared with those obtained by the mouse blood glucose method. Results with bovine insulin were in full correspondence with the in vivo results. Porcine and human insulins were 15-20% more potent by the radioreceptor assay than by the in vivo method when the mixed bovine and porcine insulin 4th International and European Standards were used, but were equivalent when compared with like materials. Average 95% confidence limits for formulated insulins in two assays were +/- 6% of the mean. The coefficient of variation on repeated assay of the same sample was 3.8%. The three dose parallel line radioreceptor assay with appropriate species species standards is a candidate biological test capable of international adoption as an alternative to in vivo animal testing of insulin.
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002417:Cattle; D002460:Cell Line; D006801:Humans; D007328:Insulin / Q000032:analysis / Q000592:standards / Q000627:therapeutic use; D008214:Lymphocytes / Q000648:ultrastructure; D051379:Mice; D011485:Protein Binding; D011786:Quality Control; D011869:Radioligand Assay / Q000379:methods*; D011972:Receptor, Insulin / Q000032:analysis*; D013552:Swine
D001786:Blood Glucose; D007328:Insulin; D011972:Receptor, Insulin